Kura Oncology (NASDAQ:KURA) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURAGet Rating) from a sell rating to a hold rating in a research report released on Tuesday morning.

KURA has been the topic of a number of other reports. Jefferies Financial Group started coverage on shares of Kura Oncology in a research report on Tuesday, February 15th. They issued a buy rating and a $35.00 target price on the stock. Credit Suisse Group increased their target price on shares of Kura Oncology from $25.00 to $27.00 and gave the company an outperform rating in a research report on Friday, February 25th. SVB Leerink dropped their target price on shares of Kura Oncology from $41.00 to $28.00 and set an outperform rating on the stock in a research report on Friday, February 25th. Finally, Zacks Investment Research downgraded shares of Kura Oncology from a hold rating to a sell rating in a research report on Thursday, May 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Buy and a consensus target price of $38.00.

Shares of NASDAQ:KURA opened at $11.62 on Tuesday. Kura Oncology has a 52 week low of $10.41 and a 52 week high of $25.70. The company’s 50 day moving average is $15.35 and its two-hundred day moving average is $14.87. The company has a market cap of $774.31 million, a PE ratio of -5.38 and a beta of 1.39.

Kura Oncology (NASDAQ:KURAGet Rating) last announced its quarterly earnings data on Wednesday, May 4th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter in the previous year, the company earned ($0.46) earnings per share. As a group, research analysts expect that Kura Oncology will post -2.19 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of KURA. Deep Track Capital LP purchased a new position in Kura Oncology during the 4th quarter worth $35,700,000. Invesco Ltd. boosted its holdings in shares of Kura Oncology by 96.8% in the third quarter. Invesco Ltd. now owns 3,000,140 shares of the company’s stock valued at $56,194,000 after acquiring an additional 1,475,350 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its holdings in shares of Kura Oncology by 51.8% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,513,756 shares of the company’s stock valued at $49,193,000 after acquiring an additional 1,198,339 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Kura Oncology by 222.0% in the first quarter. Assenagon Asset Management S.A. now owns 1,680,196 shares of the company’s stock valued at $27,018,000 after acquiring an additional 1,158,356 shares in the last quarter. Finally, Suvretta Capital Management LLC boosted its holdings in shares of Kura Oncology by 45.2% in the fourth quarter. Suvretta Capital Management LLC now owns 3,572,419 shares of the company’s stock valued at $50,014,000 after acquiring an additional 1,112,217 shares in the last quarter. 94.65% of the stock is currently owned by institutional investors.

About Kura Oncology (Get Rating)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.

Recommended Stories

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.